Last reviewed · How we verify
NCT03473119
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia
trial in Pneumonia in 600 participants. Status unknown.
19 March 2021
Quick facts
| Lead sponsor | Taipei Medical University WanFang Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 19 March 2016 |
| Primary completion | 19 March 2021 |
| Estimated completion | 19 March 2021 |
| Sites | 1 location across Taiwan |
Conditions studied
- Pneumonia — all drugs for Pneumonia →
- Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →
- Asthma — all drugs for Asthma →
Sponsor
Taipei Medical University WanFang Hospital
Who can join
18 and older, any sex, with Pneumonia or Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pneumonia is a major infectious cause of death worldwide and imposes a considerable burden on healthcare resources. Obstructive lung diseases (COPD and Asthma) are increasingly important causes of morbidity and mortality worldwide. The patients with community-acquired pneumonia (CAP), and acute exacerbations of obstructive lung diseases commonly present with similar signs and symptoms. For antibiotic use, the rapid and accurate differentiation of clinically relevant of bacterial lower respiratory tract infections from other mimics is essential. Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid has both extracellular and intracellular effects in mammalian cells. S1P is involved in many physiological processes including immune responses and endothelial barrier integrity. In term of endothelial barrier integrity, S1P plays a crucial role in protecting lungs from the pulmonary leak and lung injury. Because of the involvement in lung injury, S1P would be the potential biomarker of pneumonia. Based on the above evidence, S1P plays an essential role in the pathobiology of pneumonia was hypothesized.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.
Lucaciu A, Brunkhorst R, Pfeilschifter JM, Pfeilschifter W, et al · · 2020 · cited 53× · PMID 32580348 · DOI 10.3390/cells9061515 -
Circulating sphingosine-1-phosphate as a prognostic biomarker for community-acquired pneumonia.
Hsu SC, Chang JH, Hsu YP, Bai KJ, et al · · 2019 · cited 19× · PMID 31091284 · DOI 10.1371/journal.pone.0216963 -
Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.
Blaho VA. · · 2020 · cited 9× · PMID 32894509 · DOI 10.1007/978-3-030-50621-6_6
Verify or expand the search:
- PubMed search for NCT03473119
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pneumonia
Currently open trials in the same condition.
- NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
- NCT07251465 — A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia · active not recruiting
- NCT07311343 — Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia · Phase 4 · recruiting
- NCT07298889 — High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS · NA · recruiting
- NCT06911658 — Infectious Complications After Esophagectomy · recruiting
Other Taipei Medical University WanFang Hospital trials
Trials by the same sponsor.
- NCT07401017 — The Effects of Rosuvastatin on Running Training Adaptation and Safety · NA · not yet recruiting
- NCT07293442 — Pelvic Floor Muscle Exercise for Lower Urinary Tract Symptoms After Surgery for Benign Prostatic Hyperplasia. · NA · recruiting
- NCT07150182 — Shared Decision-Making for Families in Critical Dialysis Initiation · NA · not yet recruiting
- NCT06834425 — Efficacy of NSAID Peritendinous Injection for Acute Tendinitis · NA · active not recruiting
- NCT06862297 — Prospective Study Between Polysomnography (PSG) and Novel Ultrasonic Jaw Tracking Device in Patients with Sleep Apnea · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03473119 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University WanFang Hospital
- Last refreshed: 10 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03473119.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing